Expert process scale-up solutions for transitioning lipid nanoparticle formulations from laboratory to commercial manufacturing.
Scaling up lipid nanoparticle (LNP) processes presents unique challenges that differ fundamentally from initial formulation development. While laboratory-scale synthesis focuses on proof-of-concept and parameter exploration, scale-up requires systematic translation of critical process parameters (CPPs) to larger equipment while maintaining product quality attributes (PQAs). Key considerations include mixing efficiency at different scales, heat transfer dynamics, residence time distribution, and the inherent limitations of microfluidic platforms when transitioning from research to production volumes. Additionally, the multi-step nature of LNP manufacturing—combining lipid hydration, downsizing, and downstream processing—creates compounding complexity that must be addressed through systematic engineering studies and quality risk assessment. BOC Sciences provides comprehensive lipid nanoparticle manufacturing scale-up services, leveraging deep process understanding, scalable platform technologies, and stage-gate validation protocols to ensure successful technology transfer and commercial viability.
LNP Pilot Scale-Up and ManufacturingWe employ a systematic, risk-based approach to process scale-up that integrates quality by design (QbD) principles with practical engineering considerations. Our scale-up framework addresses the unique challenges of lipid nanoparticle formulation translation from concept to commercial reality. Each scale-up project begins with comprehensive characterization of the laboratory-scale process to establish the design space and critical quality attributes.
The transition from laboratory-scale synthesis (milligram to gram quantities) to pilot-scale production (gram to kilogram quantities) requires systematic evaluation of equipment capabilities, process parameters, and quality attribute maintenance. Our lipid nanoparticle encapsulation expertise ensures consistent payload incorporation across scale points.
Microfluidic mixing technologies offer excellent control over particle characteristics at small scales but face inherent throughput limitations. Our ionizable lipid nanoparticle platforms support multiple scale-up strategies to address these challenges.
For formulations where microfluidic approaches are not optimal, we employ conventional scale-up methodologies that leverage established engineering principles while maintaining product quality.
Real-time monitoring and control systems enable consistent product quality throughout scaled manufacturing campaigns. Our nanoparticle size analysis capabilities support inline PAT implementation.
We maintain a comprehensive portfolio of scale-up technologies to address diverse formulation requirements and production volume targets. Each platform has been validated for specific scale ranges and product profiles.
From initial technology transfer to commercial manufacturing, our scale-up expertise ensures consistent product quality at every production scale.
We implement a structured stage-gate development framework that ensures systematic progress through defined technical and quality milestones. Each stage includes predefined acceptance criteria and deliverable documentation to support seamless technology transfer. Our analytical testing services support comprehensive characterization at each stage.
| Development Stage | Key Activities | Deliverables |
|---|---|---|
| Stage 1: Feasibility Assessment | Laboratory-scale process characterization, design space exploration, critical parameter identification, small-scale optimization studies | Feasibility report, preliminary design space, initial CQA/CPP linkage, technology selection recommendation |
| Stage 2: LNP Process Development | Systematic parameter studies, DoE implementation, scale-down model development, preliminary process validation protocols | Process characterization report, design space definition, scale-down model qualification, draft control strategy |
| Stage 3: LNP Scale-Up Demonstration | Pilot-scale runs, engineering batches, process performance qualification (PPQ), scale-up factor validation | Scale-up validation report, PPQ protocols and acceptance criteria, batch records, preliminary stability data |
| Stage 4: LNP Technology Transfer | Documentation package preparation, operator training, site acceptance testing, continuous improvement protocols | Technical transfer package, validated processes, training records, ongoing support agreements |
Successful technology transfer requires more than documentation—it demands deep process understanding and systematic execution to reproduce results at the receiving site.
✔ Process Documentation Package
Comprehensive documentation including batch records, standard operating procedures, process flow diagrams, equipment specifications, and control strategy rationale. All documentation prepared in ICH-compliant format with clear version control and change management traceability.
✔ Scale-Down Model Qualification
Development and qualification of scale-down models that demonstrate equivalence between laboratory and production scale. Rigorous comparison protocols with predefined acceptance criteria for particle size, PDI, encapsulation efficiency, and other critical quality attributes.
✔ Training and Knowledge Transfer
Hands-on training programs for receiving site personnel including process theory, equipment operation, troubleshooting protocols, and deviation investigation. Training completion records and competency assessments documented for compliance purposes.
✔ Bridging Studies
Comparative studies to demonstrate process equivalence between original and receiving sites. Statistical analysis of CQA data with equivalence margins and risk assessment for any observed differences.
✔ Ongoing Technical Support
Continued technical engagement including process monitoring, troubleshooting assistance, optimization recommendations, and periodic technology reviews. Dedicated technical project management for seamless communication throughout the transfer period.
✔ Supplier Qualification Support
Assistance with raw material and equipment supplier qualification including specification development, vendor assessment protocols, and incoming material qualification testing. Our lipid nanoparticles synthesis services ensure consistent raw material quality.
Maintaining product quality through scale-up requires integrated quality systems, robust process understanding, and systematic risk management. Our quality framework ensures consistent CQA maintenance across all manufacturing scales.
Challenge: A biotech company had developed a promising mRNA-LNP vaccine candidate at laboratory scale using a commercial microfluidic system but faced significant challenges transitioning to larger-scale manufacturing quantities while maintaining consistent particle characteristics.
Solution: BOC Sciences conducted a comprehensive process characterization study at laboratory scale to establish the design space for critical parameters including flow rate ratio (FRR), total flow rate (TFR), and lipid composition effects on particle size. Based on this understanding, we implemented a parallelization strategy using our industrial microfluidic arrays, maintaining identical channel geometries and hydrodynamics while achieving the required production throughput. Process parameters were systematically translated using validated scale-up factors, and inline PAT tools provided real-time quality monitoring throughout the demonstration batches.
Result: Successfully scaled from 1 mL/min laboratory production to 500 mL/min pilot-scale manufacturing. Particle size remained consistent (85-95 nm target) across all scales, with PDI values below 0.15 achieved consistently. Encapsulation efficiency exceeded 90% at all scale points. The project was completed within 6 months, enabling the client's development program timeline.
Challenge: A pharmaceutical company needed to scale up an siRNA-LNP formulation previously produced using probe sonication to an industrial homogenizer while maintaining formulation integrity and encapsulation efficiency for their gene silencing therapeutic program.
Solution: Our team developed a scale-down model using laboratory homogenization equipment to characterize the relationship between pressure, cycle number, and product quality attributes. CFD modeling helped optimize the homogenizer valve design for the specific lipid composition. Process parameters were translated to production-scale equipment using established power-to-volume relationships and energy density calculations. Quality risk assessment identified critical parameters requiring tight control, and PAT implementation enabled real-time monitoring of particle characteristics during production runs.
Result: Achieved successful scale-up from 10 mL laboratory batches to 50 L production-scale runs. Particle size and PDI were maintained within specification limits across all scales. Encapsulation efficiency remained above 85% through systematic optimization of the homogenization pressure profile. The validated process supported the client's commercial manufacturing launch with robust batch-to-batch consistency.
Proven LNP Scale-Up Track RecordExtensive experience scaling LNP processes from milligram quantities to kilogram-scale commercial production across diverse delivery platforms and payload types.
Multiple LNP Technology PlatformsAccess to both microfluidic and conventional scale-up technologies enables optimal technology selection based on your specific formulation and volume requirements.
Integrated LNP Analytical SupportComprehensive LNP characterization and quality testing services ensure consistent monitoring throughout the scale-up journey.
Comprehensive DocumentationAll scale-up activities supported by comprehensive documentation packages suitable for health authority interactions.
End-to-End LNP CapabilityFrom initial process development through commercial manufacturing, we provide seamless technical continuity without the need for multiple technology transfer handoffs.
LNP process scale-up involves multiple levels of technical challenges. First is maintaining mixing efficiency across scales—laboratory-scale microfluidic parameters (such as flow rate, mixing unit configuration) cannot be simply linearly extrapolated to production scale; scale-up factors require reassessment. Second is thermal management—during scale-up, the contact area-to-volume ratio between lipid solution and buffer decreases, potentially causing mixing non-uniformity or temperature gradients affecting particle nucleation and growth kinetics. Third is equipment compatibility—even microfluidic chips from different manufacturers with identical specifications may have differences in surface characteristics and geometric tolerances, affecting batch consistency. Fourth is maintaining quality attributes—critical quality attributes such as particle size, PDI, and encapsulation efficiency need to remain stable throughout the entire scale range. BOC Sciences has established systematic scale-up methodologies, helping clients overcome these technical challenges through small-scale model development and cross-scale parameter mapping.
Two primary scale-up strategies exist for microfluidic LNP. The first is chip parallelization—operating multiple identical laboratory-scale chips simultaneously, with total throughput proportional to chip count, maintaining complete replication of laboratory processes. The second is geometric amplification—increasing chip channel equivalent diameter while adjusting flow rates to maintain identical Dean number or mixing intensity, achieving true linear scale-up. Each strategy has advantages and disadvantages: parallelization offers lower risk but higher equipment costs; geometric amplification is more economical but requires parameter window revalidation. BOC Sciences provides optimal scale-up strategy consultation based on client throughput requirements and budget, equipped with full-range hardware support from R&D-grade chips to industrial modules.
The key to ensuring particle size consistency during scale-up lies in identifying and maintaining scale-invariant critical parameters. For Dean flow systems, Dean number (De) and Froude number (Fr) are the core scale-invariant parameters—maintaining constant values ensures mixing kinetic consistency. For chaotic micromixers, power input per unit volume and mixing time are key parameters. Operational requirements include: high-precision flow control systems ensuring parameter stability; inline particle size monitoring enabling real-time feedback; and establishing parameter-particle size response surface models to predict scale-up effects. BOC Sciences has accumulated extensive parameter databases across LNP scale-up projects, enabling establishment of validated scale-up models for clients and significantly reducing scale-up failure risk.
Successful LNP process scale-up requires adequate preparatory work. First is comprehensive laboratory-scale characterization—before scale-up, quantitative relationships between key process parameters (KPP) and critical quality attributes (CQA) must be fully understood, establishing a reliable design space. Second is systematic evaluation of process variations—identifying and quantifying effects from raw material, utility, and operator variation sources. Third is analytical method selection and validation—ensuring testing methods used at production scale accurately reflect product quality. Fourth is development of equipment qualification and process validation protocols. BOC Sciences provides prospective services from formulation development to scale-up feasibility assessment, helping clients establish complete process knowledge systems early in projects and laying solid foundations for subsequent scale-up.
When selecting an LNP scale-up service provider, the following aspects warrant priority evaluation: hardware capabilities—whether equipped with full-series microfluidic equipment covering laboratory to production scale; process experience—whether possessing successful scale-up project case studies, particularly experience related to client target applications (such as mRNA, siRNA); scale-up methodology—whether possessing systematic scale-up strategies and parameter transfer specifications; quality systems—whether possessing comprehensive documentation management and deviation handling processes; technical support—whether providing on-site process support and issue response. BOC Sciences has cultivated the microfluidic LNP field for many years, possessing full-chain service capabilities and extensive project experience, capable of providing one-stop process scale-up solutions for clients.
